Bristol Myers Squibb Partners with Anthropic to Deploy Claude Enterprise as a Shared AI Platform Across Global Operations

Global biopharmaceutical leader Bristol Myers Squibb (BMS) recently announced a strategic agreement with AI company Anthropic to deploy Claude Enterprise as a shared intelligent platform across its global operations. The platform will cover BMS's core functions including R&D, clinical development, manufacturing, commercial, and corporate operations, aiming to connect people, systems, and institutional knowledge through AI agent capabilities to achieve enterprise-level intelligent operations.

Unlike conventional conversational AI, Claude will be deeply integrated with thousands of internal data sources at BMS, including scientific, clinical, regulatory, and commercial knowledge bases. Leveraging its agent capabilities, the system can automatically generate clinical study reports, extract scientific context from decades of internal research, or trace the root cause of manufacturing deviations in real time. Eric Kauderer-Abrams, Head of Life Sciences at Anthropic, stated that this initiative creates a unified intelligence layer for BMS, enabling knowledge to be proactively activated when needed while maintaining full enterprise governance and audit controls.

This partnership marks the first time a major pharmaceutical company has adopted AI agents as a core operational infrastructure. For BMS, it promises to accelerate drug development timelines, improve manufacturing compliance, and enhance commercial decision-making efficiency. As AI continues to penetrate the life sciences sector, this "intelligent shared" model could become a new paradigm for digital transformation in the industry.